Dr. Melissa Murray
The risks of dementia, cancer and vascular disease increase with age, but the connection between the conditions is not fully understood. Now, Mayo Clinic researchers report an intriguing ...
JACKSONVILLE, Fla. — In a new paper published in Nature Communications, Mayo Clinic researchers and collaborators report the protein-coding gene SERPINA5 may worsen tau protein ...
Septiembre es el Mes Mundial del Alzheimer, un momento para concientizar sobre la investigación que busca develar los misterios científicos que giran en torno a ...
JACKSONVILLE, Fla. — Despite decades of scientific scrutiny, Alzheimer's disease researchers have yet to work out its cause or treatment. Understanding what underlies its three distinct subtypes is thought ...
JACKSONVILLE, Fla. — In collaboration with the University of Kentucky, the University of Texas Southwest Medical Center, Rush University Medical Center, the University of Cambridge ...
JACKSONVILLE, Fla — A team of Mayo Clinic researchers found Hispanic-American patients with Alzheimer’s tend to survive significantly longer with the disease than other ethnoracial ...
Does your race influence your chances of developing Alzheimer's disease? Dr. Melissa Murray, a Mayo Clinic molecular neuroscientist, says a new Mayo Clinic study shows ...
Alzheimer’s disease is ranked as the sixth leading cause of death in the U.S., affecting more than 5 million people, according to the Alzheimer’s ...
JACKSONVILLE, Fla. — Researchers at Mayo Clinic in Florida have developed a mouse model that exhibits the neuropathological and behavioral features associated with the most common genetic form of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) and frontotemporal dementia (FTD), which are caused by a mutation in the C9ORF72 gene. They say their findings, reported today in Science, will speed further research into the molecular mechanism behind these disorders and that the animal model will offer a way to test potential therapeutic agents to halt the death of neurons in the brain and spinal cord. MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746, punsky.kevin@mayo.edu Journalists: Sound bites with Dr. Petrucelli are available in the downloads. https://www.youtube.com/watch?v=ICxKfCy_m2c
JACKSONVILLE, Fla. — By examining more than 3,600 postmortem brains, researchers at Mayo Clinic’s campuses in Jacksonville, Florida, and Rochester, Minnesota, have found that the progression of dysfunctional tau protein drives the cognitive decline and memory loss seen in Alzheimer’s disease. Amyloid, the other toxic protein that characterizes Alzheimer’s, builds up as dementia progresses, but is not the primary culprit, they say. The findings, published in Brain, offer new and valuable information in the long and ongoing debate about the relative contribution of amyloid and tau to the development and progression of cognitive dysfunction in Alzheimer’s, says the study’s lead author, Melissa Murray, Ph.D., a neuroscientist at Mayo Clinic in Jacksonville. MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746, punsky.kevin@mayo.edu Journalists: Video is available in the downloads. https://www.youtube.com/watch?v=452BcXATI4c
JACKSONVILLE, Flórida — Neurocientistas da Clínica Mayo de Jacksonville, Flórida, definiram um subtipo de doença de Alzheimer (DA) que não é bem identificada, nem tratada apropriadamente. http://youtu.be/w4xQeNQVFoc A forma variante de Doença de Alzeimer que não afeta o hipocampo, representa 11% de um total de 1.821 casos de cérebros com Doenca de Alzeimer confirmados e examinados pelos pesquisadores da Clínica Mayo, o que sugere que esse subtipo é relativamente comum na população em geral. A Associação da Alzheimer estima que 5,2 milhões de americanos convivem com a doença de Alzheimer. E como quase a metade dos casos de DA que não afeta o hipocampo não é diagnosticada corretamente, é possível significar que bem mais de 600.000 americanos têm essa variante da doença de Alzheimer, afirmam os pesquisadores.
JACKSONVILLE, Florida — Neurocientíficos de la Clínica Mayo en Jacksonville, Florida, han definido un subtipo de la enfermedad de Alzheimer (EA), que dicen no es ni reconocido ni tratado adecuadamente. http://youtu.be/w4xQeNQVFoc La variante de la enfermedad de Alzheimer que no afecta el hipocampo, conformó el 11% de los 1.821 cerebros confirmados con EA y examinados por investigadores de la Clínica Mayo, lo que sugiere que este subtipo está relativamente extendido en la población general. La Asociación de Alzheimer estima que 5,2 millones de estadounidenses viven con esta patología. Y con casi la mitad de los pacientes con la EA que no afecta el hipocampo siendo mal diagnosticados, podría significar que más de 600.000 estadounidenses presentan esta variante de la enfermedad, dicen los investigadores.
JACKSONVILLE, Fla. — Neuroscientists at Mayo Clinic in Florida have defined a subtype of Alzheimer’s disease (AD) that they say is neither well recognized nor treated appropriately. http://youtu.be/w4xQeNQVFoc The variant, called hippocampal sparing AD, made up 11 percent of the 1,821 AD-confirmed brains examined by Mayo Clinic researchers — suggesting this subtype is relatively widespread in the general population. The Alzheimer’s Association estimates that 5.2 million Americans are living with AD. And with nearly half of hippocampal sparing AD patients being misdiagnosed, this could mean that well over 600,000 Americans make up this AD variant, researchers say.